Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias

Argüeso, Rosa; Campuzano, Raquel; Egocheaga, Isabel; Escobar, Carlos; Fácila, Lorenzo; López, Pedro Mata; Rossi, M; Mansilla, Carmen Rus; Duque, José Antonio Alarcón; Arrarte, Vicente; Barón, Gonzalo; Barrios, Vivencio; Carro, Amelia; Castro, Almudena; Cosı́n-Sales, Juan; Olmo, Rosa Fernández; Martínez, José Gámez; Huelmos, Ana; Sandín, Miriam; Saltijeral, Adriana; Valle-Muñoz, Alfonso; Arribas, Fernando; Congost, Gemma Berga; Bueno, Héctor; Evangelista, Arturo; Ferreira‐González, Ignacio; Navarro, Manuel Jiménez; Marín, Francisco; Isla, Leopoldo Pérez de; Sambola, Antonia; Vázquez, Rafael; Viana-Tejedor, Ana; Ibáñez, Borja; Alfonso, Fernándo

doi:10.1016/j.rec.2019.11.019

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For patients already receiving lipid-lowering drug therapy, high apo B levels have been shown to be a more accurate marker of myocardial infarction risk than LDL-C [7]. Moreover, in 2019, the European Society of Cardiology and the European Atherosclerosis Society recommend Lp(a) measurement at least once in a lifetime to identify the risk of cardiovascular disease [8].…”

Section: Introductionmentioning

confidence: 99%

Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years

Seo

Shin

2022

Korean J Clin Lab Sci

View full text Add to dashboard Cite

The relationship between lipoprotein(a) and dyslipidemia is not clear. This study was therefore undertaken to investigate the relationship between lipoprotein(a) and dyslipidemia in elderly patients over 60 years. From 2014 to 2020, a total of 2,580 adults aged 60 years or older (73.31±7.24 years, 1,954 males) were enrolled in the study. The patients had checked into a general hospital, and data were obtained for lipoprotein(a), LDL-C, TG, HDL-C, hs-CRP, HbA1c, sex, age, BMI, dyslipidemia diagnosis, and use of lipid-lowering agents. BMI and HbA1c showed no correlation with lipoprotein(a), but hs-CRP (r=0.138), LDL-C (r=0.097), HDL-C (r=-0.089), TG (r=-0.073), and age (r=0.072) were significantly correlated to lipoprotein(a). The partial correlation between lipoprotein(a) and LDL-C, which was adjusted for variables, was significant only in the male gender (r=0.158, P＜0.001). As the odds ratio of the 4 th quartile of lipoprotein(a) (OR=1.376, 95% CI=1.038∼1.822) for dyslipidemia was found to be significant in this study when the level of LDL-C, the primary target, could not be reduced even by taking lipid-lowering drugs, we propose that lipoprotein(a) should also be included among the several factors considered as secondary targets. Our results indicate that studies on various lipid factors considering the sex, age, types and use of lipid-lowering agents, are warranted.

show abstract

Section: Introductionmentioning

confidence: 99%

Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years

Seo

Shin

2022

Korean J Clin Lab Sci

View full text Add to dashboard Cite

show abstract

Effect of mobile-based cognitive behavior therapy (CBT) on lowering of blood lipid levels in atherosclerotic cardiovascular disease (ASCVD) patients: study protocol for a multicenter, prospective, randomized controlled trial

Hong

Luan

Liu

et al. 2022

Trials

View full text Add to dashboard Cite

Background Atherosclerotic cardiovascular disease (ASCVD) remains a major source of mortality in China. Convincing evidence has demonstrated that the reduction of low-density lipoprotein cholesterol (LDL-C) is correlated with lowering ASCVD risk. The efficacy of lifestyle management in lipid levels reduction has been confirmed in numerous studies. However, considering that low compliance to lifestyle management has limited the benefits of lowering lipid levels, cognitive behavior therapy (CBT) is proposed as a solution to improve clinical outcomes. The objective of this trial is to compare the LDL-C outcome in ASCVD patients receiving mobile device-based CBT to a control group, with both groups under standard pharmacological treatments. Methods This trial is designed as a multicenter, prospective randomized controlled trial with a 6-month follow-up. Mean LDL-C level and the percentage of different LDL-C levels, coefficient of variation of LDL, General Self-Efficacy Scale (GSEs), quality of life index (QL-index), etc., between the two groups at baseline, 1, 3, and 6 months will be measured. Discussion This trial should demonstrate that the implementation of mobile-based CBT intervention will be potentially effective in lowering LDL-C levels in ASCVD patients. Trial registration Chinese Clinical Trial Registry (ChiCTR2100046775) [registered: 2021/5/28].

show abstract

Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias

Cited by 2 publications

References 29 publications

Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years

Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years

Effect of mobile-based cognitive behavior therapy (CBT) on lowering of blood lipid levels in atherosclerotic cardiovascular disease (ASCVD) patients: study protocol for a multicenter, prospective, randomized controlled trial

Contact Info

Product

Resources

About